Citius’ first FDA decision date is approaching — and its CEO has millions on the line
PharmaVoice,
Listen to the article 6 min This audio is auto-generated. Please let us know if you have feedback.
Listen to the article 6 min This audio is auto-generated. Please let us know if you have feedback.
Preclinical study demonstrates that adding LYMPHIR to anti-PD-1 treatment augments anti-tumor activity and improves overall…
Preclinical study demonstrates that adding LYMPHIR to anti-PD-1 treatment augments anti-tumor activity and improves overall…
Preclinical study demonstrates that adding LYMPHIR to anti-PD-1 treatment augments anti-tumor activity and improves overall…